(Press-News.org) The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.
At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea.
"We wanted to conduct this study because pemetrexed plus platinum chemotherapy is the most commonly used regimen for treating patients with non-squamous NSCLC whose cancer does not have mutations that can be targeted by specific inhibitors," Kim explained.
"However, docetaxel plus platinum is another effective regimen in the first line treatment of lung cancer and there has been no direct comparison of pemetrexed plus cisplatin versus docetaxel plus cisplatin."
In the study, researchers randomly assigned patients with chemotherapy-naive cancer to 3-weekly cisplatin 70 mg/m2 in addition to either docetaxel 60 mg/m2 or pemetrexed 500mg/m2 for up to 4 cycles.
They recorded a median progression-free survival of 4.7 months in those who received the pemetrexed combination, and 4.6 months among those who received docetaxel.
However, the rate of serious adverse events was higher in the docetaxel group, they found, with 24 serious adverse events recorded among pemetrexed patients, and 42 in the docetaxel arm.
Kim notes that recruitment into the study was halted early when pemetrexed maintenance treatment was approved in Korea and its use became widespread. "As we stopped recruitment prematurely, we could not prove non-inferiority between the arms. However, the pemetrexed plus cisplatin arm was less toxic than the docetaxel plus cisplatin arm, while there was no significant difference in progression-free survival and response rate," Kim said.
The researchers are continuing to follow patients in the trial to study whether there is any difference in overall survival between the arms.
Commenting on the study, Dr Solange Peters from the University Hospital of Lausanne, Switzerland, noted: "The various available platinum-based regimen demonstrate quite similar activity in NSCLC."
"While a dedicated larger trial published by Scagliotti in 2008 was able to show some superiority of platinum in combination with pemetrexed in non-squamous NSCLC, this trial also confirms its better tolerability, reinforcing most current international NSCLC treatment guidelines," Peters said.
INFORMATION: END
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
2014-09-27
ELSE PRESS RELEASES FROM THIS DATE:
Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
2014-09-27
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid.
In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment with the combination of pemetrexed and cisplatin than those whose tumours expressed high levels.
"Thymidylate synthase is one of the proteins that is targeted by pemetrexed which ...
French studies measure benefits of colorectal cancer screening
2014-09-27
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid.
Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976. They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began ...
Crizotinib treatment effective against ROS1-positive lung cancer
2014-09-27
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.
"Prior to this study, there were a handful of reports describing marked responses to crizotinib ...
Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show
2014-09-27
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.
"When chemotherapy is administered after the first trimester of pregnancy, we cannot discern any problems in the children," says lead author Dr Frederic Amant, KU Leuven and University Hospitals Leuven in Belgium. "Fear about the risks of chemotherapy administration should not be a reason to terminate a pregnancy, delay cancer treatment for the mother, or ...
Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia
2014-09-27
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
"Anorexia and cachexia are among the most troubling and distressing symptoms of advanced cancer, for both patients and their families," says the study's principal investigator, Dr Jennifer Temel from the Department of Medicine, Massachusetts General Hospital, Boston, USA.
Symptoms of the wasting syndrome can include a loss of weight and muscles, ...
Afatinib improves progression-free survival in head and neck cancer
2014-09-27
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.
Presented at the ESMO 2014 Congress in Madrid, the Lux-Head & Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median progression-free survival of ...
Rolapitant reduces nausea and vomiting in Phase III trial
2014-09-27
Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.
Dr Martin Chasen, lead author and medical director, Palliative Care, Ottawa Hospital Cancer Centre, Canada, said: "This agent makes a significant difference in the way people tolerate their chemotherapy. Patients experienced no loss in quality of life and, in fact, many saw meaningful improvements. One of the patients in the rolapitant cohort reported that ...
Countries must work together to stop organ traffickers, says researcher
2014-09-27
The author of new research into organ trafficking has called for a concerted international effort to confront the problem.
Dr Ana Manzano, of the School of Sociology and Social Policy at the University of Leeds, says a combination of factors means nobody knows definitively how many organs are being traded across the world.
She said: "Unless these issues are addressed and countries work together to take firm action against the traffickers, more people who have their organs trafficked will die.
"Even in the UK, although the World Health Organization has identified us ...
Smoke still rising from King Fire in California
2014-09-26
Over 96,004 acres have been burned by the King Fire since it began on September 13, 2014. The fire is currently 68% contained, and the cause of the fire is arson. Just a few days ago, (Sept. 23) the fire was only 38% contained so progress on extinguishing it continues. Over 7,700 personnel are battling this fire.
A Pacific system came through the fire area yesterday (9/25) bringing 0.6-0.9 inches of rain. The observed fire activity was minimal with smoldering in interior pockets of the heavier fuels. A low pressure system will become the dominate feature today (9/26) ...
Agricultural fires blaze in Borneo
2014-09-26
The skies over Indonesian Borneo were filled with the smoke from hundreds of fires set deliberately to clear farmland. A shroud of thick, gray smoke hung over the area when the Aqua satellite captured this image on September 25, 2014. The Moderate Resolution Imaging Spectroradiometer (MODIS) instrument aboard the Aqua satellite detected dozens of fires (locations outlined in red) across the entire region from Central Borneo to South Borneo and even on East Laut Island.
Widespread burning in lowland forests on Borneo is an annual, manmade occurrence. People use fires ...